Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis (Q35189289)

7 August 2017

1 reference

title

Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis (English)

1 reference

antiphospholipid syndrome

7 August 2017

main subject

1 reference

based on heuristic

inferred from title

venous thromboembolism

1 reference

10

Y Shoenfeld

1 reference

7 August 2017

1

P L Meroni

1 reference

7 August 2017

4

A Tincani

1 reference

7 August 2017

9

M A Khamashta

1 reference

7 August 2017

7

T Koike

1 reference

7 August 2017

Ronald H. W. M. Derksen

series ordinal

3

object named as

R H W M Derksen

1 reference

7 August 2017

8

J-C Piette

1 reference

7 August 2017

M Moia

2

1 reference

7 August 2017

J A McIntyre

series ordinal

5

1 reference

7 August 2017

J M M C Arnout

series ordinal

6

1 reference

7 August 2017

publication date

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

12

1 reference

7 August 2017

issue

7

1 reference

7 August 2017

page(s)

504-507

1 reference

Hypercoagulability syndromes

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Recurrent venous thromboembolism: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Antithrombotic therapy for venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Duration of anticoagulation for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Managing oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Hemorrhagic complications of anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Antiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Warfarin for venous thromboembolism - walking the dosing tightrope

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203303LU389OA

10.1191/0961203303LU389OA

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference